EyePoint Pharmaceuticals. has filed a patent for compounds that activate Tie-2 and inhibit HPTP-beta, potentially providing therapy for vascular disorders such as retinopathies, ocular edema, and ocular neovascularization. The patent claims a method of increasing cell survival by administering a therapeutically-effective amount of the compound to a patient in need. GlobalData’s report on EyePoint Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights EyePoint Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on EyePoint Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. EyePoint Pharmaceuticals's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Compound for treating vascular disorders and increasing cell survival

Source: United States Patent and Trademark Office (USPTO). Credit: EyePoint Pharmaceuticals Inc

A recently filed patent (Publication Number: US20230265087A1) describes a method for increasing cell survival in patients by administering a specific compound. The compound is represented by a formula and has various substituents and functional groups. The method involves administering a therapeutically-effective amount of the compound to a patient in need.

The patent claims specify different variations of the compound and their respective effects on cell survival. For example, claim 25 states that administering the compound increases the production of pAkt in the patient, which is associated with cell survival. The compound can be administered through various routes such as intravenous, oral, topical, or nasal administration, as mentioned in claim 26.

The patent also covers a pharmaceutical composition comprising the compound. Claim 30 describes the composition, which includes the compound and may also contain additional active ingredients, carriers, stabilizers, diluents, or dispersing agents. The additional active ingredients can be antimicrobial agents, anti-inflammatory agents, or anesthetics, as mentioned in claim 32.

The patent provides specific details on the compound's structure and the conditions under which it can be administered. It also describes a method for measuring the increase in cell survival using protein electrophoresis and blotting, as mentioned in claim 28. The administration of the compound is expected to result in a significant increase in cell survival, as indicated by a signal of about 300% above the control, as stated in claim 29.

Overall, this patent presents a method and pharmaceutical composition for increasing cell survival in patients by administering a specific compound. The compound's structure and administration details are provided, along with its potential effects on cell survival. The patent also covers the inclusion of additional active ingredients in the pharmaceutical composition.

To know more about GlobalData’s detailed insights on EyePoint Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies